ESMO Virtual 2020: Impact of immunotherapy on quality of life
In this video interview, Dr Jeffrey Kirshner from the Haematology-Oncology Associates [...]
Sapanisertib is tolerable and shows activity in advanced kidney cancer
In a phase I study to look at the safety [...]
Patients ‘left in the dark’ by the NHS over cancer treatments
Macmillan Cancer Support has recently published the results from their [...]
Selecting therapy for poor-risk advanced kidney cancer
In this video interview, Dr Earle Burgess from the Levine [...]
Monitoring treatment toxicities in patients with renal cell carcinoma
Drs Dan George and Tian Zhang from the Duke Prostate [...]
Assessing and managing adverse events to immunotherapies
In this video interview, Brenda Martone discusses the clinical nurse [...]
Real world use of pazopanib after immunotherapy for advanced kidney cancer
A study published in Clinical Genitourinary Cancer last month describes [...]
ESMO 2019: Neurologic complications of immunotherapy
This interview with Dr Matthias Preusser from the Medical University of [...]
Alternative 2/1 sunitinib dosing schedule superior to 4/2 dosing schedule for metastatic kidney cancer
A recent study, published in Clinical Genitourinary Cancer reports a [...]
Immunotherapy combinations show promise for advanced kidney cancer
A review in JAMA Oncology presents evidence to suggest that [...]
